Mitapivat · Pyrukynd

Small molecule

Also known as AG-348

Approvedregulatory verdict

Evidence outlook

Approved: Pyruvate Kinase Deficiency

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Latest reported trial: NCT03548220 · Phase 3 · met primary endpoint · grade pending

Also in development:Sickle Cell Disease · Phase 3 · investigational in the US · under FDA reviewTransfusion-Dependent Beta Thalassemia · Phase 3 · investigational in the USapproved in the US as Aqvesme (same FDA application)

Also approved (5)
EU
  • Adults with anemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia (release dated 2026-05-22)biospace.com
  • Treatment of pyruvate kinase deficiency (PK deficiency) in adult patients (holder Agios Netherlands B.V.)EMA
Product first approved 2022
AE
  • Adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia (Agios release dated 2026-03-02)
Product first approved 2026biospace.com
SA
  • Adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia (Agios release dated 2025-08-04)
Product first approved 2025finviz.com
UK
  • Treatment of PK deficiency in adult patients (Great Britain, via EC Decision Reliance Procedure)
biospace.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (8)
Pyruvate Kinase Deficiency
NCT05175105 · Agios Pharmaceuticals, Inc.
2022-06-06 – 2030-01 · Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia
What this study did
NCT05144256 · Agios Pharmaceuticals, Inc.
2022-06-08 – 2029-06 · Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia
What this study did
NCT03853798 · Agios Pharmaceuticals, Inc.
2019-03-21 – 2024-07-03 · Pyruvate Kinase Deficiency
What this study did
Sickle Cell Disease
Transfusion-Dependent Beta Thalassemia
Other / comorbidity
NCT07517133 · Agios Pharmaceuticals, Inc.
2026-09 – 2032-03 · Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
What this study did
Phase 2/3 (1)
Sickle Cell Disease
Phase 2 (5)
Pyruvate Kinase Deficiency
NCT02476916 · Agios Pharmaceuticals, Inc.
2015-06-26 – 2025-04-02 · Pyruvate Kinase Deficiency
What this study did
Sickle Cell Disease
NCT06286046 · Agios Pharmaceuticals, Inc.
2026-03 – 2028-12 · Sickle Cell Disease, Nephropathy
What this study did
Other / comorbidity
NCT03692052 · Agios Pharmaceuticals, Inc.
2019-03-20 – 2030-09-30 · Thalassemia
What this study did
NCT07055243 · University Health Network, Toronto
2025-10-20 – 2029-10 · Anemia
What this study did
NCT05935202 · EuroBloodNet Association
2023-12-21 – 2029-03-30 · Hereditary Red Blood Cell Disorder (Disorder)
What this study did
Phase 1/2 (1)
Sickle Cell Disease
NCT04610866 · National Heart, Lung, and Blood Institute (NHLBI)
2020-12-09 – 2028-02-28 · Sickle Cell Disease, Hemolytic Anemia
What this study did
Phase 1 (12)
Sickle Cell Disease
NCT04000165 · National Institutes of Health Clinical Center (CC)
2019-07-11 – 2021-06-21 · Sickle Cell Disease
What this study did
Other / comorbidity
NCT06648824 · Agios Pharmaceuticals, Inc.
2024-10-17 – 2024-12-03 · Healthy Participants
What this study did
NCT05610657 · Agios Pharmaceuticals, Inc.
2023-01-10 – 2023-07-21 · Moderate Hepatic Impairment
What this study did
NCT04696393 · Agios Pharmaceuticals, Inc.
2021-01-06 – 2021-03-19 · Healthy Volunteers
What this study did
NCT04565678 · Agios Pharmaceuticals, Inc.
2020-09-21 – 2020-12-03 · Healthy Volunteers
What this study did
NCT04472832 · Agios Pharmaceuticals, Inc.
2020-06-17 – 2020-11-23 · Healthy Volunteers
What this study did
NCT03991312 · Agios Pharmaceuticals, Inc.
2019-06-20 – 2019-09-10 · Healthy Volunteers
What this study did
NCT03397329 · Agios Pharmaceuticals, Inc.
2017-10-03 – 2017-11-13 · Healthy Volunteers
What this study did
NCT03250598 · Agios Pharmaceuticals, Inc.
2017-08-09 – 2017-10-09 · Healthy, Japanese, Non-Asian
What this study did
NCT02149966 · Agios Pharmaceuticals, Inc.
2014-05 – 2014-11 · Healthy Volunteer
What this study did
NCT02108106 · Agios Pharmaceuticals, Inc.
2014-03 – 2014-08 · Healthy Volunteer
What this study did
Phase 4 (1)
Pyruvate Kinase Deficiency
NCT05777993 · Agios Pharmaceuticals, Inc.
2023-07-06 – 2031-08 · Pyruvate Kinase Deficiency, Anemia, Hemolytic, Sickle Cell Disease, Thalassemia
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Sickle Cell Disease: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Mitapivat (Pyrukynd): this drugPhase 3Small moleculePyruvate kinasenot yet gradedNo reviewed efficacy summary in this indication
Crizanlizumab-Tmca (Adakveo)ApprovedMonoclonal antibodyP-selectinPartial signalFeatured results are non-efficacy only in this race
Exagamglogene Autotemcel (Casgevy)ApprovedGene therapy / editingBCL11A erythroid enhancer (gene editing)Weak signalNo reviewed efficacy summary in this indication
Hydroxyurea (Droxia)ApprovedSmall moleculeRibonucleotide reductasenot yet gradedNo reviewed efficacy summary in this indication
Hydroxyurea (Siklos)ApprovedSmall moleculeRibonucleotide reductasenot yet gradedNo reviewed efficacy summary in this indication
Hydroxyurea (Xromi)ApprovedSmall moleculeRibonucleotide reductaseWeak signalNo reviewed efficacy summary in this indication
L-Glutamine (Endari)ApprovedSmall moleculeAmino AcidReliable signal
NCT01179217: The Number of Occurrences of Sickle Cell Crises (48 weeks): L-glutamine 3 Number of crises (range 0 to 15) | 100% Maltodextrin 4 Number of crises (range 0 to 15)
Lovotibeglogene Autotemcel (Lyfgenia)ApprovedGene therapy / editingBeta-globin gene addition (betaA-T87Q)not yet gradedNo reviewed efficacy summary in this indication
EtavopivatPhase 3—Pyruvate kinasenot yet gradedNo reviewed efficacy summary in this indication
Decitabine / Tetrahydrouridine (NDec)Phase 2Small moleculeDNMT1 (DNA methyltransferase 1)not yet gradedNo reviewed efficacy summary in this indication
HBI-002Phase 2Small moleculeCarbon monoxide (CO)-based gas therapeutic; oral liquid CO formulationnot yet gradedNo reviewed efficacy summary in this indication
ITU512Phase 1/2Small moleculeWIZ transcription factornot yet gradedNo reviewed efficacy summary in this indication
Nula-CelPhase 1/2Gene or cell therapy (subtype unspecified)HBB gene (sickle mutation correction)not yet gradedNo reviewed efficacy summary in this indication
Ristoglogene AutogetemcelPhase 1/2Gene therapy / editingHBG1/HBG2 promotersnot yet gradedNo reviewed efficacy summary in this indication
DISC-3405Phase 1Monoclonal antibodyTMPRSS6 (matriptase-2)not yet gradedNo reviewed efficacy summary in this indication
SCD-101Phase 1——not yet gradedNo reviewed efficacy summary in this indication
VAS-101Phase 1——not yet gradedNo reviewed efficacy summary in this indication
Iloprost (Ventavis)DiscontinuedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Renizgamglogene AutogedtemcelDiscontinuedGene or cell therapy (subtype unspecified)HBG1/HBG2 promotersnot yet gradedNo reviewed efficacy summary in this indication
Voxelotor (Oxbryta)DiscontinuedSmall moleculeHemoglobin S (HbS)Reliable signal
NCT03036813: Haemoglobin response (>1 g/dL rise at week 24): voxelotor 1500 mg 46/90, 900 mg 30/92, placebo 6/92

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Pyrukynd (Mitapivat) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (2)
February 2028 (1)
Phase 1/2Sickle Cell DiseaseActive not recruiting
Est. primary completion 2028-02-28 · NCT04610866 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Hereditary Red Blood Cell Disorder (Disorder)Active not recruiting
Est. primary completion 2028-09-30 · NCT05935202 · CT.gov ↗
What to watch
2029 (5)
March 2029 (1)
Phase 3Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-ThalassemiaRecruiting
Est. primary completion 2029-03 · NCT07517133 · CT.gov ↗
What to watch
June 2029 (1)
Phase 3Transfusion-Dependent Beta ThalassemiaRecruiting
Est. primary completion 2029-06 · NCT07506863 · CT.gov ↗
What to watch
August 2029 (2)
Phase 3Sickle Cell DiseaseRecruiting
Est. primary completion 2029-08 · NCT07656415 · CT.gov ↗
What to watch
Phase 4Sickle Cell DiseaseEnrolling by invitation
Est. primary completion 2029-08 · NCT05777993 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2AnemiaActive not recruiting
Est. primary completion 2029-10 · NCT07055243 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

1 February 2027FDA action dateMitapivat sickle cell sNDA PDUFA goal date extended to 1 February 2027
US, FDA · Source ↗

Recent

12 May 2026Filing submittedAgios submits mitapivat sNDA for sickle cell disease
US, FDA · AGIOS PHARMACEUTICALS, INC. · Source ↗
November 2025Topline resultRISE UP Phase 3 of mitapivat in sickle cell disease (NCT05031780): hemoglobin response met; pain crisis rate not significant
Agios Pharmaceuticals, Inc. · Source ↗